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ABSTRACT
Fusarium species frequently implicated in human infections include F. solani, F. oxysporum and
F. moniliforme. Among immunocompetent patients, tissue breakdown (as caused by trauma, severe
burns or foreign body) is the risk factor for fusariosis. Infections include keratitis, onychomycosis and
occasionally peritonitis and cellulitis. Treatment is usually successful and requires removal of the
foreign body as well as antifungal therapy. Among immunocompromised patients, mainly patients with
haematological malignancies, Fusarium spp. are the second most common pathogenic mould. Risk
factors for disseminated fusariosis include severe immunosuppression (neutropenia, lymphopenia,
graft-versus-host disease, corticosteroids), colonisation, tissue damage, and receipt of a graft from an
HLA-mismatched or unrelated donor. Clinical presentation includes refractory fever (> 90%), skin
lesions and sino-pulmonary infections (75%). Type of skin lesions includes ecthyma-like, target, and
multiple subcutaneous nodules. Skin lesions lead to diagnosis in > 50% of patients and precede
fungemia by  5 days. In contrast to disseminated aspergillosis, disseminated fusariosis can be
diagnosed by blood cultures in 40% of patients. Histopathology reveals hyaline acute-branching septate
hyphae similar to those found in aspergillosis. Mortality from fusarial infections in immunocompro-
mised patients ranges from 50% to 80%. Host immune status is the single most important factor
predicting outcome. Persistent neutropenia and corticosteroid therapy signiﬁcantly affect survival.
Optimal treatment has not been established. Anecdotal successes have been reported with various
agents (high-dose amphotericin B, lipid-based amphotericin B formulations, itraconazole, voriconazole)
and with cytokine-stimulated granulocyte transfusions. Preventing fusariosis relies on detection and
treatment of cutaneous damage prior to commencing immunosuppression and decreasing environ-
mental exposure to Fusaria (via air and water).
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INTRODUCTION
The genus Fusarium is a common soil saprophyte
and an important plant pathogen. The organism
causes a broad spectrum of human disease,
including mycotoxicosis and infections which
can be locally invasive or disseminated.
MICROBIOLOGY
Fusarium spp. are agents of hyalohyphomycosis
along with other fungi such as Penicillium spp.,
Scedosporium spp., Acremonium spp., Paecilomyces
spp., Aspergillus spp., Scopulariopsis spp. and
others [1]. ‘Hyalohyphomycosis’ is a term that
describes fungal infections caused by moulds
whose basic tissue form is in the nature of
hyaline, light-coloured, hyphal elements that are
branched or unbranched, occasionally toruloid,
and without pigment in their wall [2].
Fusarium spp. grow rapidly on many media
(without cycloheximide which is inhibitory). On
potato dextrose agar, Fusarium spp. produce
white, lavender, pink, salmon, or grey colonies
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(which readily change colour) with velvety to
cottony surfaces [3].
Microscopically, the hyphae of Fusarium in
tissue resemble those of Aspergillus spp.; the
ﬁlaments are hyaline, septate and 3–8 lm in
diameter. They typically branch at acute or right
angles. The production of both fusoid macrocon-
idia (hyaline, multicellular, banana-like clusters
with foot cells at the base of the macroconidium)
and microconidia (hyaline, unicellular, ovoid to
cylindrical in slimy head or chains) are character-
istic of the genus Fusarium. If microconidia are
present, the shape, number of cells (usually one to
three), and mode of cell formation (chains or false
heads) are important in identiﬁcation. Chlamydo-
spores are sometimes present and appear singly,
in clumps or in chains, and their walls may be
rough or smooth [3].
Fusarium can be distinguished from Acremo-
nium by its curved, multicellular macroconidia,
while Cylindrocarpon is distinguished from Fusa-
rium by its straight to curved macroconidia that
lack foot cells [3]. The identiﬁcation of Fusarium
spp. may be difﬁcult and is well described by
Nelson et al. [4].
Fusarium spp. possess several virulence factors
including the production of tricothecene and
other mycotoxins. These mycotoxins can suppress
humoral and cellular immunity, and cause tissue
breakdown. Fusarium spp. also have the ability to
adhere to prosthetic material (contact lenses,
catheters), and to produce proteases and colla-
genases [4].
EPIDEMIOLOGY
Fusarium spp. are widely distributed in soil, plants
and air. They are common in tropical and tem-
perate regions but are also found in desert, alpine
and arctic areas [4]. In a survey of airborne fungi
conducted in the USA, Fusarium spp. were more
commonly recovered from air samples than were
Aspergillus spp. [5]. Fusarium spp. colonised 17%
of throat specimens of 27 nonhospitalised healthy
adults [6]. These organisms can also colonise the
conjunctival sac, especially in diseased eyes [7].
Wind and rain effectively Fusarium disperse [8].
Fusarium spp. are the most common cause of
fungal keratitis world-wide. In a series of 391
incidences of infectious keratitis in Thailand, 34
(12%) were fungal and Fusarium was the most
common fungus recovered [9]. Another series of
1352 fungal keratitis cases in India conﬁrmed this
ﬁnding (37%).
In severely immunocompromised patients, this
fungus can cause disseminated disease and has
recently emerged as the second most common
pathogenic mould (after Aspergillus) in high-risk
patients with haematological cancer, and in recip-
ients of solid organ [10] and allogeneic bone
marrow or stem cell transplants [11–13]. In
the latter patient population, the distribution of
fusariosis is bimodal, with peaks observed before
and several weeks after engraftment. At one US
institution, the incidence of fusarial infection was
1.2% among 750 allogeneic and 0.2% among 1537
autologous marrow transplant recipients during a
10-year period [11]. A review of fusarial infections
in patients with acute leukaemia in Italy showed
an incidence of 0.06% [14]. While the incidence in
Europe has remained stable over the past
20 years, it has signiﬁcantly increased at one US
institution from 0.5 to 3.8 cases per year from 1975
to 1995 [11]. In this institution, the hospital water
system was found to be a reservoir for Fusarium
spp. [15]. In another US institution, 31 cases of
invasive fusariosis were documented among 5589
stem cell transplant recipients (0.55%) during a
14-year period, with an increase in the number of
these patients during the late 1990s [13].
RISK FACTORS
Tissue breakdown from direct trauma or the
presence of a foreign body in a colonised patient
are the usual risk factors for infections in non-
immunosuppressed patients. These infections are
mainly localised and include keratitis after trau-
ma or among contact lens wearers [16], onyc-
homycosis among individuals who walk
barefooted and, rarely, peritonitis in patients
undergoing continuous ambulatory peritoneal
dialysis, cellulitis after injury [17] and others.
Disseminated fusariosis among previously
healthy individuals can develop in the setting of
a severe burn injury [18,19].
Risk factors for disseminated fusariosis include
severe immunosuppression (mainly patients
with haematological malignancies) in addition to
colonisation and tissue damage. More speciﬁcally,
neutropenia, lymphopenia, graft-versus-host dis-
ease, corticosteroid therapy or any other immu-
nosuppressive treatment, are considered risk
factors for disseminated fusariosis [11,20–22]. In
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a recent review of invasive fungal infections
among stem cell transplant recipients, multiple
myeloma, and receipt of a graft from an HLA-
mismatched or unrelated donor were signiﬁcantly
associated with fusarium infections [13].
CLINICAL MANIFESTATIONS
Infections by Fusarium spp. can be divided into
foreign-body associated, single organ invasion
and disseminated fusariosis [4]. Mycotoxicosis
caused by Fusarium spp. will not be included in
this review.
Single organ invasion
Keratitis
Fusarium spp. are a frequent cause of corneal
damage in developing countries in the tropics
[23], and are the most frequent cause of fungal
keratitis in the USA [24]. The main predisposing
factor is ocular trauma due to the implantation of
vegetable or soil matter [16,25,26]. An additional
risk factor for Fusarium keratitis is the presence of
a pathological corneal condition and concomitant
therapy with topical steroids and antibacterial
antibiotics. Topical natamycin is the treatment of
choice because of its excellent antifusarial activity,
corneal penetration and safety proﬁle, but amph-
otericin B ointment can also be used [27,28].
Chlorhexidine may have potential as an inexpen-
sive topical agent for fungal keratitis and war-
rants further assessment as a ﬁrst-line treatment
in conditions where microbiological facilities and
a range of antifungal agents may not be available
[29]. Systemic antifungal treatment may be useful
in severe mycotic keratitis and surgery may be
required in refractory infections or when serious
complications are likely to occur.
Endophthalmitis
Fusarial endophthalmitis can develop between 2
and 22 weeks after the onset of fusarial keratitis
or following surgical and nonsurgical trauma [37].
Onychomycosis
Fusarium spp. may invade the great toenails after
soil contamination, especially in individuals who
walk in open sandals or barefooted. The most
common clinical presentations include proximal
subungual onychomycosis with or without par-
onychia, and white superﬁcial onychomycosis
[38,39]. Distal subungual onychomycosis can also
occur following trauma or a dermatophyte infec-
tion [40]. Fusarium spp. were reported to be the
causative agent of 9–44% of the nail invasions
caused by nondermatophytic moulds [38,41–43].
A combined strategy of systemic itraconazole,
systemic terbinaﬁne, topical terbinaﬁne after nail
plate avulsion, and ciclopirox nail lacquer was
able to cure only 40% of 26 patients with
fusarium onychomycosis [38]. Aspergillus onyc-
homycosis, on the other hand, responded very
well to this therapy.
Although onychomycosis as a result of Fusa-
rium spp. infection usually behaves as a localised
infection in immune competent individuals, it
could also represent the portal of entry for
disseminated disease in immunocompromised
patients [4,44,45].
Cutaneous infections
In immune competent individuals, localised cuta-
neous infections may develop in the setting of
initial colonisation and the presence of excessive
moisture or trauma (including burn). Skin lesions
may vary including granulomas, ulcers, nodules,
mycetomas, necrosis, panniculitis and intertrigo
[4,46]. As reported in a recent review of cutaneous
infections by Fusarium spp. [45], in patients
presenting with localised cutaneous infections,
immunocompetent patients (10 of 13) had more
frequently a history of skin breakdown than those
who were immunocompromised (11 of 20). While
cutaneous infections in the former population
were characterised by localised involvement, slow
progression and good response to therapy, those
in the latter population who presented as rapidly
progressive usually disseminated lesions with
poor response to antifungal agents. The cutaneous
infections secondary to disseminated disease will
be described later.
Foreign-body associated fusariosis
Keratitis in contact lens wearers
Fusarium spp. can also contaminate the contact
lens paraphernalia or the lens itself, especially
after improper care. In windy conditions, Fusa-
rium spp. can also contaminate the lens during
use. This fungus can penetrate the matrix of the
soft contact lens with increasing microbial growth
in lenses with high water content [30]. Fusarium
keratitis can also develop among users of daily
Dignani and Anaissie Human fusariosis 69
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10 (Suppl. 1), 67–75
disposable soft contact lenses [31]. Treatment
often requires removal of the lens and topical
treatment with natamycin but may require sur-
gery in refractory patients [31–36].
Peritonitis following continuous ambulatory peritoneal
dialysis
The clinical presentation is usually insidious, with
fever, abdominal pain and decreasing drainage
from the peritoneal catheter. Fungi can either
plug or invade the catheter. Treatment often
requires catheter removal and systemic antifungal
therapy [47–55].
Catheter-associated fungemia
Fusarium spp. can rarely plug and invade the wall
of a central venous catheter and lead to fungemia
[56–58]. Treatment includes catheter removal and
systemic antifungal therapy.
Other single organ infections
Less frequently, Fusarium spp. can also cause
osteomyelitis, arthritis, otitis, sinusitis and brain
abscess. Fusarium was the cause of 1% of 83 cases
of mycotic otitis of the external ear in Gabon,
Central Africa [59]. F. solani was found in, and
was able to germinate in, the middle ear of
agricultural workers [60]. Four of ﬁve cases of
fusarium osteomyelitis were reported in healthy
individuals following surgery or trauma [61–64].
Successful outcome resulted from a combination
of surgical and medical treatment. Bone involve-
ment by Fusarium spp. may also occur in the
setting of disseminated disease [65]. Fusarium
septic arthritis has been reported in two patients
after trauma, responded to surgery and ampho-
tericin B [66,67]. Sinusitis in a diabetic cancer
patient [68] and an isolated brain abscess in a
patient with chronic infectious mononucleosis
syndrome [69] have also been reported.
Disseminated disease
Clinical presentation
Disseminated infections occur most commonly in
patients with haematological malignancies and
occasionally in patients with extensive burns [11].
The Fusarium spp. most frequently implicated as
human pathogens include F. solani, F. oxysporum,
F. moniliforme and less commonly, F. anthophilum,
F. chlamydosporum, F. dimerum, F. equiseti, F. licheni-
cola, F. napiforme, F. proliferatum, F. semitecum and
F. verticilloides (the less common species listed in
alphabetical order) [11,12,70–73]. Disseminated
infection usually presents as persistent fever
refractory to antibacterial and antifungal agents.
Other presenting features include sinusitis and ⁄ or
rhinocerebral infection, cellulitis at the site of
skin breakdown, endophthalmitis, painful skin
lesions, pneumonia, myositis and infections of the
central nervous system [11,21]. Almost any organ
can be involved but the most frequently affected
is the skin (70–90%), followed by lungs and
sinuses (70–80%) [11]. Three types of cutaneous
lesions can be observed: multiple, at times pain-
ful, subcutaneous nodules and ecthyma-like le-
sions, and less commonly, bullae or target lesions
consisting of the ecthyma-like lesions surrounded
by a thin rim of erythema [45]. Some of these
lesions represent an evolution of the same lesions
observed at different ages. Extensive cellulitis of
the face or the extremities, with or without
fascitis, has also been described [74]. Pleuritic
chest pain, fever, cough and haemoptysis occur in
patients with pulmonary involvement and are
indistinguishable from pulmonary aspergillosis.
Indeed, the clinical features of patients with
disseminated fusarial infection are similar in
many respects to those with disseminated asper-
gillosis [11]. Unlike aspergillosis, however, infec-
tion with Fusarium spp. is associated with a high
incidence of skin and subcutaneous lesions and
with positive blood cultures [11,21,45,75–77].
Among patients undergoing solid organ trans-
plantation, fusarial infections tend to be more
localised, occur later after transplantation and
have a better outcome than among patients with
haematological cancer or recipients of bone mar-
row transplantation [10].
In a recent review of cutaneous fusariosis in 259
patients including 232 who were immunocom-
promised, a higher rate of skin lesions was
present among neutropenic (78%) than non-neu-
tropenic patients (45%) and those with dissemin-
ated skin lesions were more likely to have fusarial
fungemia [45]. Skin lesions involved practically
any skin site, with predominance on the extrem-
ities, and took different forms as described above.
The lesions evolved rapidly, usually over a few
days (range 1–5 days) and lesions at different
stages of evolution were described in many
patients (usually a combination of papules,
nodules and necrotic lesions), sometimes along
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with myalgias (suggesting muscle involvement).
The skin was the primary site of infection leading
to disseminated fusariosis in 16 patients (mainly
at sites of onychomycosis and less frequently at
sites of trauma or insect bite). The pattern of skin
lesions did not appear to be associated with any
particular species of Fusarium.
Diagnosis
In patients with severe immunosuppression, a
high index of suspicion for disseminated fusari-
osis should be raised when mould fungemia is
reported, or when preceding or concomitant toe
or ﬁnger cellulitis, or cutaneous or subcutaneous
lesions are present [72,78].
Skin is a very important source for diagnosis. In
one report, skin lesions were the single source of
diagnosis of fusarial infection in 55% of patients.
In most cases, skin lesions preceded fungemia by
a median of 5 days (range 1–10 days), but they
also developed after the diagnosis of fungemia
(up to 13 days later) [45]. Histopathological exam-
ination of skin lesions showed hyaline acute-
branching septate hyphae invading the skin and
extending into the blood vessels, with thrombosis
and necrosis in those patients with metastatic
lesions [45].
In contrast to disseminated aspergillosis, dis-
seminated fusariosis can be diagnosed by blood
cultures in 40% of patients [11,72]. The rate of
positive blood cultures increases to 60% in the
presence of disseminated skin lesions, while
fungemia is extremely rare in patients with
localised skin infections [45].
As with aspergillosis, the radiological ﬁndings
of pulmonary fusarial infection range from non-
speciﬁc inﬁltrates (most commonly) to nodular
and ⁄ or cavitary lesions, depending on the timing
of the study.
Thedeﬁnitive diagnosis of fusariosis requires the
isolation of Fusarium spp. from clinical specimens
(blood, skin, sinuses, lungs, other). Culture identi-
ﬁcation is important because of the histopatholog-
ical similarities between Fusarium and other
members of the hyalohyphophomycosis family
and the different susceptibilities of these pathogens
to antifungal agents. LikeAspergillus spp., Fusarium
spp. invade blood vessels causing thrombosis and
tissue infarction and appear in tissues as acute
branching septate hyphae [4,11]. Tissue diagnosis
of fusariosis can be made by immunohistological
staining, using polyclonal ﬂuorescent antibody
reagents that distinguish Aspergillus spp. from
Fusarium spp. [79]. In-situ hybridisation may also
help to distinguish Fusarium spp. from Aspergillus
and Pseudoallescheria in tissue sections with a 100%
positive predictive value [80].
Treatment
Prompt therapy of localised disease is critical to
prevent progression to disseminated infection
and includes surgical debridement, and probably
systemic antifungal chemotherapy [11,76,81].
The optimal treatment for disseminated fusa-
riosis remains unclear. Voriconazole, itraconazole
and the polyenes (amphotericin B and its lipid
formulations) [82–87] have been associated with
some success. In the USA, voriconazole is the only
agent with an indication for treating refractory
fusariosis.
Fusarium spp. are some of the most drug-
resistant fungi. Data on their in-vitro susceptibility
to various antifungal agents indicate low suscep-
tibility to 5-ﬂucytosine, ﬂuconazole and ampho-
tericin B [88–90] and variable susceptibility to
itraconazole, voriconazole and posaconazole
[89,91–99]. F. solani seems to be somewhat more
susceptible to amphotericin B but less susceptible
to voriconazole than F. oxysporum [100].
The echinocandins caspofungin [101], anidula-
fungin, and micafungin [102,103] have no in-vitro
activity against Fusarium spp.
In severely neutropenic patients, treatment
with granulocyte or granulocyte–macrophage col-
ony-stimulating factors (G- or GM-CSF) and CSF-
stimulated white blood cell transfusions may also
be considered [11,104–106]. Recently, a combined
approach of liposomal amphotericin B, voricon-
azole, surgery and granulocyte transfusions was
associated with a successful outcome in a child
with severe aplastic anaemia and disseminated
infection by F. oxysporum [106].
Debridement or resection of all infected tissues
(sinuses, ocular tissues, soft tissue, bone, other) is
recommend but frequently impossible because of
severe thrombocytopenia. Catheter removal may
be of beneﬁt if the catheter is the source of the
fusariosis.
Outcome
Disseminated fusariosis is a life-threatening dis-
ease whose outcome is very much inﬂuenced by
the host immune status. Overall mortality of
fusarial infections in immunocompromised
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patients ranges from 50% to 80% [11,45,72,107].
In a retrospective study that included 84 patients
with fusariosis, factors associated with poor sur-
vival by multivariate analysis included persistent
neutropenia and therapy with corticosteroids. The
actuarial survival of patients with both persistent
neutropenia and corticosteroid therapy was 0%,
compared to 67% who had neither of these two
factors present, 30% for those on corticosteroids
(but with adequate neutrophil counts), and 4%
for those whose only negative prognostic factor
was persistent neutropenia [108].
These data are in agreement with other reports
that describe very high mortality in persistently
neutropenic patients [11,45,72,107].
Disseminated skin lesions may be a marker of
poor outcome in non-neutropenic patients. In a
retrospective study of 259 patients with fusariosis
[45], a higher mortality was observed among
patients with skin lesions (70% vs. 56%), partic-
ularly among those who had an adequate neu-
trophil count throughout the course of their
illness. In this group of patients, the mortality
rate for patients with metastatic skin lesions was
67% vs. 21% for those with localised lesions. The
mortality among neutropenic patients was high
regardless of whether the lesions were localised
or metastatic (64% vs. 77%), respectively.
Prevention
Because of the high morbidity and mortality of
disseminated fusariosis, every effort should be
made to prevent these infections, and to enhance
the patient’s immune status, perhaps by tapering
or discontinuing immunosuppressive agents or
shortening the duration of neutropenia. We also
recommend that patients likely to receive severely
immunosuppressive therapy undergo a thorough
skin evaluation prior to commencing immuno-
suppression, to identify areas of tissue breakdown
and evaluate these lesions with culture and
biopsy and antifungal treatment if Fusarium spp.
are identiﬁed. In addition, severely immunocom-
promised patients with skin or other exposed
tissue breakdown should avoid exposure to envi-
ronmental sources of Fusarium spp. such as tap
water. Indeed, we have shown that hospital water
may be contaminated with Fusarium spp. and can
lead to aerosolisation (especially after showering)
and to patient exposure and disease [109]. Avoid-
ing exposure to tap water can be accomplished
by the use of sterile sponge baths instead of
showering (to minimise aerosolisation), and by
drinking sterile water only during periods of
severe immunosuppression. Cleaning water-
related environmental surfaces (bathroom ﬂoors)
results in a signiﬁcant decrease in the airborne
concentration of pathogenic moulds in the bath-
rooms of a bone marrow transplant unit [110].
Thus, adequate cleaning of the bathroom is
recommended prior to showering (for those
patients who insist on showering during the
period of major immunosuppression).
Because of the risk of relapse in immunosup-
pressed patients with prior fusarial infections
[111], secondary prophylaxis should be consid-
ered. The agent of choice would be the one
associated with clinical response during the initial
infection. Consideration should also be given to
using prophylactic G-CSF or GM-CSF-stimulated
granulocyte transfusions following initiation of
severely myelosuppressive chemotherapy.
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